Physician profile
Galen M Meyer
NPI 1881692903
$5,311.22
in general payments reported to CMS, 2019-2025
41 companies · $387 in 2025
The $387 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $682 · 2020: $401 · 2021: $772 · 2022: $1,048 · 2023: $1,073 · 2024: $948 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,407.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $764.07 | 2019-2024 | |
| Teleflex LLC | $566.46 | 2022-2025 | Urolift, Barrigel |
| Coloplast Corp | $373.11 | 2019-2025 | Speedicath |
| Boston Scientific Corporation | $365.99 | 2022-2025 | Rezum Generator, Lithovue, Spaceoar Vue System - 10ml |
| Janssen Biotech, INC. | $351.40 | 2019-2025 | Erleada, Akeega |
| Astellas Pharma US INC | $319.13 | 2019-2023 | Xtandi |
| Karl Storz Endoscopy-America | $301.44 | 2019-2024 | N.A. |
| Janssen Scientific Affairs, LLC | $216.49 | 2023-2024 | Erleada, Balversa, Pipeline |
| Bayer Healthcare Pharmaceuticals INC. | $215.32 | 2019-2023 | |
| Urogen Pharma, INC. | $168.30 | 2021-2025 | |
| Endo Pharmaceuticals INC. | $157.15 | 2019-2021 | |
| Cook Medical LLC | $142.55 | 2021-2025 | Resonance |
| Pfizer INC. | $131.29 | 2020-2025 | |
| Allergan, INC. | $118.61 | 2019-2021 | |
| Amgen INC. | $109.22 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Galen Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.